A Real‐World Experience of Prognostic Factors of Survival Outcomes in a Taiwanese Population With Unresectable Hepatocellular Carcinoma Treated With First‐Line Lenvatinib
Shou‐Wu Lee, Yi‐Jie Huang, Hsin‐Ju Tsai, Ying‐Cheng Lin, Chia‐Chang Chen, Teng‐Yu Lee, Yen Chun‐Peng · 2026
Read A Real‐World Experience of Prognostic Factors of Survival Outcomes in a Taiwanese Population With Unresectable Hepatocellular Carcinoma Treated With First‐Line Lenvatinib by Shou‐Wu Lee, Yi‐Jie Huang, Hsin‐Ju Tsai, Ying‐Cheng Lin, Chia‐Chang Chen, Teng‐Yu Lee, Yen Chun‐Peng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13179444.txt.
Description
Shou-Wu Lee and six co-authors report real-world results for a liver cancer drug in Taiwan in a study from two thousand twenty-six. Lenvatinib is a first-line option when liver tumors cannot be cut out, but trial results may not match everyday practice. The team looked for traits that predict who does well.
One hundred eleven patients treated over three years were reviewed. About a third responded, and four in five gained disease control. Median survival was seventeen months. Patients with the best liver grade, and those also given local therapy, lived clearly longer. A tumor marker below a set cutoff predicted slower progression. The authors back tailored treatment plans and call for prospective confirmation.
Catalog record
| CREATOR | Shou‐Wu Lee, Yi‐Jie Huang, Hsin‐Ju Tsai, Ying‐Cheng Lin, Chia‐Chang Chen, Teng‐Yu Lee, Yen Chun‐Peng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |